home / stock / bpmc / bpmc news


BPMC News and Press, Blueprint Medicines Corporation From 05/23/20

Stock Information

Company Name: Blueprint Medicines Corporation
Stock Symbol: BPMC
Market: NASDAQ
Website: blueprintmedicines.com

Menu

BPMC BPMC Quote BPMC Short BPMC News BPMC Articles BPMC Message Board
Get BPMC Alerts

News, Short Squeeze, Breakout and More Instantly...

BPMC - FDA Approval Could Be a Game-Changer for Deciphera Pharmaceuticals

Deciphera Pharmaceuticals (NASDAQ: DCPH) , a biopharmaceutical company based in Waltham, Mass., received a double shot of good news last week ... and has been climbing ever since. As of midday Friday, the biopharma's stock is now nearly $8 higher than it was at the end of the previous week -...

BPMC - CytomX Slumps On Data, And Other News: The Good, Bad And Ugly Of Biopharma

CytomX Stock Slumps on Disappointing Probody Data CytomX Therapeutics ( CTMX ) slumped as the company provided updates about its two lead drug candidates CX-072 and CX-2009. The company had also recently reported its financial results for the first quarter of 2020 and offered business upda...

BPMC - Deciphera shares halted pending news

Nasdaq has suspended trading in Deciphera Pharmaceuticals ( DCPH +6.6% ) pending the release of news. More news on: Deciphera Pharmaceuticals, Inc., Blueprint Medicines Corporation, Healthcare stocks news, Stocks on the move, Read more ...

BPMC - FDA rejects Blueprint Medicines' avapritinib in fourth-line GIST

Blueprint Medicines (NASDAQ: BPMC ) reports that it has received a Complete Response Letter (CRL) from the FDA regarding its marketing application for avapritinib in fourth-line gastrointestinal tumor (GIST). More news on: Blueprint Medicines Corporation, Bayer Aktiengesellschaft, Deciph...

BPMC - Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

CAMBRIDGE, Mass. , May 15, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has issued a co...

BPMC - Blueprint Medicines Announces Data Presentations Highlighting Significant Progress in Advancing RET-Altered Cancer and Systemic Mastocytosis Programs

CAMBRIDGE, Mass. , May 14, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to present updated clinical data for pralsetinib in RET-al...

BPMC - Blueprint Medicines up 11% on prospects of RET inhibitor pralsetinib

Blueprint Medicines ( BPMC +10.7% ) is poised for its best one-day gain in a month on the heels of a note from SVB Leerink on RET inhibitor pralsetinib (BLU-667). More news on: Blueprint Medicines Corporation, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, Read mo...

BPMC - Spotlight On Tech Momo, Bitcoin Halving And 13Fs

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

BPMC - Blueprint Medicines (BPMC) Q1 2020 Earnings Call Transcript

Image source: The Motley Fool. Blueprint Medicines   (NASDAQ: BPMC) Q1 2020 Earnings Call May 06, 2020 , 8:30 a.m. ET Operator Continue reading

BPMC - Blueprint Medicines Corporation's (BPMC) CEO Jeff Albers on Q1 2020 Results - Earnings Call Transcript

Blueprint Medicines Corporation (BPMC) Q1 2020 Earnings Conference Call May 6, 2020, 08:30 AM ET Company Participants Kristin Hodous - Senior Manager, IR Jeff Albers - CEO Christy Rossi - Chief Commercial Officer Mike Landsittel - CFO Andy Boral - Chief Medical Officer Con...

Previous 10 Next 10